The science in this sentence holds up well. The citation list does not — one of the three references it points to could not be found.
What Was Claimed?
The sentence makes a careful, hedged statement about what scientists have proposed, not about what has been proven to work. It says two things. First, that researchers have put forward a mechanism: cannabinoid receptors of the CB2 type, sitting on microglia (the brain's resident immune cells), might be a way to dial down pain that is driven by inflammation in the nervous system. Second, that fibromyalgia — a condition of chronic, body-wide pain — is one such inflammation-linked pain state, because two processes have been tied to it: "central sensitization" (the nervous system becoming over-reactive to pain signals) and microglial activation. The sentence then backs all of this up with three references.
Anyone reading or relying on a sentence like this — a clinician, an investor evaluating a therapeutics company, a writer building on the science — wants to know two separate things: is the science accurate, and are the citations real?
What Did We Find?
On the science, the sentence is accurate. The idea that CB2 receptors on microglia can modulate inflammation-driven pain is not a fringe notion; it is a mainstream research hypothesis stated in many peer-reviewed reviews from 2009 through 2023. Foundational reviews establish that CB2 receptors are found mainly on microglia and that switching them on changes how those cells behave. A 2023 review devoted entirely to "microglial CB2 receptors in pain modulation" connects this directly to the pain circuitry of the spinal cord. Three independent sources, different authors, fourteen years apart — the first proposition checks out.
The fibromyalgia part also checks out. A 2025 review of fibromyalgia and inflammation highlights the role of microglial activation; a landmark 2019 brain-imaging study provided direct evidence of glial activation in fibromyalgia patients; and a 2024 review lists central sensitization as one of the core processes investigated in the condition. Both phenomena the sentence names are genuinely implicated in fibromyalgia in the published literature.
Where the sentence falls down is its third citation. "Cabral & Griffin-Thomas, 2009" is a real, well-known paper. "Stella, 2010" is a real, well-known paper. But "Chen et al., 2023" could not be identified. A systematic search of PubMed — four separate queries pairing a Chen author with 2023 and the relevant topic terms — turned up nothing that matches. The only genuinely on-topic 2023 papers on CB2, microglia and pain were written by authors named Xu and Zhou, not Chen. The one cannabinoid paper by a first author Chen in 2023 is about a different cannabinoid compound and Alzheimer's disease, not this topic at all.
So two of the three sub-claims are verified, and one fails. Not because the science was contradicted, but because one of the three references the sentence offers as proof appears to be misattributed or invented.
What Should You Keep In Mind?
The "Chen et al., 2023" reference looks like the kind of citation that an AI text generator hallucinates, or that gets garbled in a careless edit — the first two references are correct and specific, while the third has the right shape but no real paper behind it. If this sentence appears in a document you are evaluating, treat that as a small red flag about how the document was assembled, and do not reproduce the Chen citation without finding the real intended source.
One more caution: the sentence only claims the mechanism has been proposed. That is true. It does not claim cannabinoid therapy actually treats fibromyalgia — and that stronger claim would not hold, because clinical results for cannabinoids in fibromyalgia are inconsistent and unproven. Read the sentence for exactly what it says.
How Was This Verified?
Each of the eight supporting sources was checked by fetching the source page and confirming the exact quoted wording appears on it, and the missing reference was investigated through systematic database searches. See the structured proof report, the full verification audit, or re-run the proof yourself.
What could challenge this verdict?
Four counter-investigations were run against the emerging verdict.
First, is the CB2-on-microglia mechanism a genuine proposal or a fringe idea? Searches of PubMed and the web confirm it is a well-established research hypothesis articulated across many independent reviews from 2009 to 2023 — not fringe. A related caution surfaced and is worth flagging to any reader: the clinical efficacy of cannabinoids in fibromyalgia specifically remains inconsistent and unproven. This does not undermine SC1, because the claim asserts only that the mechanism "has been proposed," not that it works clinically — but it does mean the sentence should not be read as evidence that cannabinoid therapy treats fibromyalgia.
Second, is microglial activation in fibromyalgia disputed? The TSPO-PET evidence (Albrecht et al.) has acknowledged limitations — the TSPO tracer is not microglia-specific and sample sizes are modest — and the field remains active. But no authoritative source rejects the broader implication, which is supported by converging evidence from imaging, cerebrospinal-fluid cytokines, and multiple reviews. The claim's hedged word "implicated" is accurate, so SC2 stands.
Third, does "Chen et al., 2023" correspond to a real publication? This was the decisive adversarial check. Four systematic PubMed queries were run: Chen as author in 2023 combined with, respectively, (CB2 or cannabinoid) + microglia + pain; cannabinoid + microglia; fibromyalgia; and CB2 + pain. None returned a first-author-Chen 2023 paper matching the attributed topic. The single CB2-author hit had first author Nan; the on-topic 2023 reviews were authored by Xu et al. and Zhou et al. The conclusion is that the citation cannot be identified — a pattern consistent with a misattributed or hallucinated reference. This finding is what makes SC3 fail; it does not force the verdict to UNDETERMINED, because SC1 and SC2 are independently established.
Fourth, does the claim require a fibromyalgia-specific CB2/microglia proposal? Under the natural grammatical reading it does not — fibromyalgia is named as an instance of neuroinflammatory pain states, a reading bridged by SC2. A stricter reading would be only weakly supported; this scope limitation is disclosed and does not change the verdict.
Source: proof.py JSON summary
Proof Logic
Sub-claim 1 — the CB2-on-microglia mechanism has been proposed. Three independently published peer-reviewed sources, spanning 2009 to 2023 with no shared authorship, articulate this mechanism. Cabral & Griffin-Thomas (2009) state that CB2 expression "has been localized primarily to microglia, the resident macrophages of the CNS" (B1), in a review whose title is explicitly "therapeutic prospects for neuroinflammation." Stella (2010) establishes that CB1 and CB2 receptors "are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells' differentiation, functions and viability" (B2) — i.e., CB2 sits on microglia and its activation modulates microglial function. Xu et al. (2023), in a review titled "Microglial Cannabinoid CB2 Receptors in Pain Modulation," report that "the expression of CB2 receptors is significantly increased in activated microglia in the spinal cord" (B3), directly connecting microglial CB2 to nociceptive (pain) circuitry. Three verified sources meet the consensus threshold of three, so SC1 holds (A1).
Sub-claim 2 — central sensitization and microglial activation are implicated in fibromyalgia. Three independent sources cover the two conjoined phenomena. For microglial activation: Findeisen et al. (2025), a narrative review of fibromyalgia neuroinflammation, notes "a growing focus on processes occurring in the dorsal root ganglia and the role of maladaptive microglial cell activation" (B4); and Albrecht et al. (2019), a multi-site positron-emission-tomography study, was designed because "mounting evidence suggests a role for neuroinflammation" and went on to provide direct imaging evidence of "brain glial activation in FM" (B5). For central sensitization: Jurado-Priego et al. (2024) state that "three underlying processes in fibromyalgia have been investigated. These include central sensitization…" (B6). Together the set establishes both conjuncts, meeting the threshold of three, so SC2 holds (A2).
Sub-claim 3 — citation integrity. The claim explicitly names three references. Two resolve cleanly. Cabral & Griffin-Thomas (2009) is a real publication — Expert Reviews in Molecular Medicine 11:e3, DOI 10.1017/S1462399409000957 (B7). Stella (2010) is a real publication — Glia 58(9):1017–1030, DOI 10.1002/glia.20983 (B8). The third reference, "Chen et al., 2023," could not be identified. Systematic PubMed searches (detailed in the adversarial checks) returned no first-author-Chen 2023 publication on CB2/microglia/pain or fibromyalgia; the only genuinely on-topic 2023 papers have first authors Xu and Zhou, not Chen. Because only 2 of the 3 named references resolve, SC3 fails (A3): 2 is below the threshold of 3.
Compound result. Of three sub-claims, two hold and one fails (n_holding = 2 of 3; claim_holds = False). The compound claim is therefore PARTIALLY VERIFIED.
Source: author analysis
The science in this sentence holds up well. The citation list does not — one of the three references it points to could not be found.
What Was Claimed?
The sentence makes a careful, hedged statement about what scientists have proposed, not about what has been proven to work. It says two things. First, that researchers have put forward a mechanism: cannabinoid receptors of the CB2 type, sitting on microglia (the brain's resident immune cells), might be a way to dial down pain that is driven by inflammation in the nervous system. Second, that fibromyalgia — a condition of chronic, body-wide pain — is one such inflammation-linked pain state, because two processes have been tied to it: "central sensitization" (the nervous system becoming over-reactive to pain signals) and microglial activation. The sentence then backs all of this up with three references.
Anyone reading or relying on a sentence like this — a clinician, an investor evaluating a therapeutics company, a writer building on the science — wants to know two separate things: is the science accurate, and are the citations real?
What Did We Find?
On the science, the sentence is accurate. The idea that CB2 receptors on microglia can modulate inflammation-driven pain is not a fringe notion; it is a mainstream research hypothesis stated in many peer-reviewed reviews from 2009 through 2023. Foundational reviews establish that CB2 receptors are found mainly on microglia and that switching them on changes how those cells behave. A 2023 review devoted entirely to "microglial CB2 receptors in pain modulation" connects this directly to the pain circuitry of the spinal cord. Three independent sources, different authors, fourteen years apart — the first proposition checks out.
The fibromyalgia part also checks out. A 2025 review of fibromyalgia and inflammation highlights the role of microglial activation; a landmark 2019 brain-imaging study provided direct evidence of glial activation in fibromyalgia patients; and a 2024 review lists central sensitization as one of the core processes investigated in the condition. Both phenomena the sentence names are genuinely implicated in fibromyalgia in the published literature.
Where the sentence falls down is its third citation. "Cabral & Griffin-Thomas, 2009" is a real, well-known paper. "Stella, 2010" is a real, well-known paper. But "Chen et al., 2023" could not be identified. A systematic search of PubMed — four separate queries pairing a Chen author with 2023 and the relevant topic terms — turned up nothing that matches. The only genuinely on-topic 2023 papers on CB2, microglia and pain were written by authors named Xu and Zhou, not Chen. The one cannabinoid paper by a first author Chen in 2023 is about a different cannabinoid compound and Alzheimer's disease, not this topic at all.
So two of the three sub-claims are verified, and one fails. Not because the science was contradicted, but because one of the three references the sentence offers as proof appears to be misattributed or invented.
What Should You Keep In Mind?
The "Chen et al., 2023" reference looks like the kind of citation that an AI text generator hallucinates, or that gets garbled in a careless edit — the first two references are correct and specific, while the third has the right shape but no real paper behind it. If this sentence appears in a document you are evaluating, treat that as a small red flag about how the document was assembled, and do not reproduce the Chen citation without finding the real intended source.
One more caution: the sentence only claims the mechanism has been proposed. That is true. It does not claim cannabinoid therapy actually treats fibromyalgia — and that stronger claim would not hold, because clinical results for cannabinoids in fibromyalgia are inconsistent and unproven. Read the sentence for exactly what it says.
How Was This Verified?
Each of the eight supporting sources was checked by fetching the source page and confirming the exact quoted wording appears on it, and the missing reference was investigated through systematic database searches. See the structured proof report, the full verification audit, or re-run the proof yourself.
Before any verdict ships, the engine runs adversarial searches for evidence that could break the proof. 4 were run here.
| subject | the peer-reviewed literature on CB2-receptor activation on microglia, neuroinflammatory pain, and fibromyalgia, plus the three references the claim cites |
|---|---|
| threshold | |
| note | The claim is taken as a complete unit - the sentence AND its parenthetical citation list - and decomposed into three sub-claims joined by AND. SC1 and SC2 test the two scientific propositions; SC3 tests the integrity of the three references the claim names. All three sub-claims must hold for the claim to be fully PROVED. The claim's verbs ('has been proposed', 'have been implicated') are deliberately hedged, hypothesis-level language; this proof verifies exactly that hedged form and does not test clinical efficacy. |
| sub-claims | SC1 |
| SC2 | |
| SC3 |
SC1 (CB2/microglia mechanism proposed): 3 >= 3 = True
SC2 (central sensitization & microglial activation in fibromyalgia): 3 >= 3 = True
SC3 (all three cited references resolve): 2 >= 3 = False
compound (all sub-claims hold): 2 == 3 = False
n_holding = 2 of n_total = 3 sub-claims. Because some but not all sub-claims hold, the verdict is PARTIALLY VERIFIED.
Source: proof.py inline output (execution trace)
Four counter-investigations were run against the emerging verdict.
First, is the CB2-on-microglia mechanism a genuine proposal or a fringe idea? Searches of PubMed and the web confirm it is a well-established research hypothesis articulated across many independent reviews from 2009 to 2023 — not fringe. A related caution surfaced and is worth flagging to any reader: the clinical efficacy of cannabinoids in fibromyalgia specifically remains inconsistent and unproven. This does not undermine SC1, because the claim asserts only that the mechanism "has been proposed," not that it works clinically — but it does mean the sentence should not be read as evidence that cannabinoid therapy treats fibromyalgia.
Second, is microglial activation in fibromyalgia disputed? The TSPO-PET evidence (Albrecht et al.) has acknowledged limitations — the TSPO tracer is not microglia-specific and sample sizes are modest — and the field remains active. But no authoritative source rejects the broader implication, which is supported by converging evidence from imaging, cerebrospinal-fluid cytokines, and multiple reviews. The claim's hedged word "implicated" is accurate, so SC2 stands.
Third, does "Chen et al., 2023" correspond to a real publication? This was the decisive adversarial check. Four systematic PubMed queries were run: Chen as author in 2023 combined with, respectively, (CB2 or cannabinoid) + microglia + pain; cannabinoid + microglia; fibromyalgia; and CB2 + pain. None returned a first-author-Chen 2023 paper matching the attributed topic. The single CB2-author hit had first author Nan; the on-topic 2023 reviews were authored by Xu et al. and Zhou et al. The conclusion is that the citation cannot be identified — a pattern consistent with a misattributed or hallucinated reference. This finding is what makes SC3 fail; it does not force the verdict to UNDETERMINED, because SC1 and SC2 are independently established.
Fourth, does the claim require a fibromyalgia-specific CB2/microglia proposal? Under the natural grammatical reading it does not — fibromyalgia is named as an instance of neuroinflammatory pain states, a reading bridged by SC2. A stricter reading would be only weakly supported; this scope limitation is disclosed and does not change the verdict.
Source: proof.py JSON summary
references & relationships
Related work — context, sources, supplements
- Cabral & Griffin-Thomas (2009) — CB2 localized to microglia PMCPMCID:PMC2768535doidoi:10.1017/S1462399409000957
- Stella (2010) — CB1/CB2 on microglia PMCPMCID:PMC2919281doidoi:10.1002/glia.20983
- Stella (2010) — truncated DOI form captured by prose-scan regex (separate follow-up; not a real DOI) doidoi:10.1002/glia
- Xu et al. (2023) — Microglial CB2 in pain modulation PMCPMCID:PMC9917135
- Findeisen et al. (2025) — Fibromyalgia neuroinflammation PMCPMCID:PMC11852494
- Albrecht et al. (2019) — TSPO-PET glial activation in fibromyalgia PMCPMCID:PMC6541932
- Jurado-Priego et al. (2024) — Fibromyalgia pathophysiology PMCPMCID:PMC11275111
audit trail · Detailed Evidence
All 8 citations verified.
Original audit log
All eight empirical citations resolved to the same outcome, so the per-citation fields are reported once and then noted individually.
B1 — Cabral & Griffin-Thomas (2009). Status: verified. Method: full_quote (the quote was an exact match; coverage_pct is null, as expected for a full-quote match). Fetch mode: snapshot. Verbatim: yes. Impact: not applicable (verified).
B2 — Stella (2010). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes. The quote contains a typographic apostrophe (U+2019) in "cells'"; it was matched after Unicode normalization within the full-quote pass.
B3 — Xu et al. (2023). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
B4 — Findeisen et al. (2025). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
B5 — Albrecht et al. (2019). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
B6 — Jurado-Priego et al. (2024). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
B7 — bibliographic record for Cabral & Griffin-Thomas (2009). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
B8 — bibliographic record for Stella (2010). Status: verified. Method: full_quote. Fetch mode: snapshot. Verbatim: yes.
Note on fetch mode. All eight citations were verified with fetch mode snapshot. PubMed Central (pmc.ncbi.nlm.nih.gov) blocks or truncates automated HTTP requests non-deterministically — an identical request returns the full article on one run and a roughly 21 KB stub on the next. To make this proof deterministic and offline-reproducible, proof.py disables live fetching (by setting the verifier module's requests reference to None, a documented monkeypatch pattern) and verifies every quote against committed full-page snapshots in the snapshots/ directory, captured 2026-05-20 with a browser user-agent. A re-runner therefore obtains the same result regardless of PMC's current behavior. The snapshot files are part of the proof bundle.
Source: proof.py JSON summary evidence[*].verification
| Field | Value |
|---|---|
| Subject | The peer-reviewed literature on CB2-receptor activation on microglia, neuroinflammatory pain, and fibromyalgia, plus the three references the claim cites |
| Claim type | compound_empirical |
| Proof direction | affirm |
| Time-sensitive | No |
| Compound operator | AND |
| SC1 | CB2-on-microglia mechanism proposed for neuroinflammatory pain — operator >=, threshold 3 |
| SC2 | Central sensitization and microglial activation implicated in fibromyalgia — operator >=, threshold 3 |
| SC3 | All three cited references resolve to real publications — operator >=, threshold 3 |
Source: proof.py JSON summary claim_formal
The natural-language claim asserts, about the scientific literature, that (a) activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, that this class of states includes chronic widespread pain syndromes such as fibromyalgia, and that central sensitization and microglial activation have been implicated in fibromyalgia; and (b) three named references support this — Cabral & Griffin-Thomas (2009), Stella (2010), and Chen et al. (2023).
The formal interpretation treats the claim as a compound of three sub-claims joined by AND. SC1 tests the first scientific proposition (the CB2/microglia mechanism has been proposed for neuroinflammatory pain). SC2 tests the second scientific proposition (central sensitization and microglial activation are implicated in fibromyalgia). SC3 tests the integrity of the claim's citation apparatus (each of the three named references resolves to a real, identifiable publication). The compound operator is AND: all three sub-claims must hold for the claim, taken as a complete unit, to be fully PROVED.
SC1 and SC2 are operationalized as source-counting sub-claims with a threshold of three independently published peer-reviewed sources — the standard consensus floor. SC3 is operationalized as a citation-integrity count: the claim names exactly three references, so the threshold is three and the sub-claim holds only if all three resolve.
Formalization scope. Two aspects of the natural-language claim are operationalized in ways that should be made explicit. First, the verbs "has been proposed" and "have been implicated" are treated at face value as hedged, hypothesis-level assertions; the proof tests whether the mechanism has been proposed and the phenomena implicated, and does not test clinical efficacy of cannabinoid therapy in fibromyalgia (which is separately noted in the adversarial checks as inconsistent/unproven). Second, the clause "including chronic widespread pain syndromes such as fibromyalgia" is read as naming fibromyalgia as an instance of the neuroinflammatory pain states for which the mechanism is proposed — a reading bridged by SC2. Under this reading SC1 does not require a study specifically proposing CB2-on-microglia agonism as a fibromyalgia therapy. A stricter reading (a dedicated fibromyalgia-specific CB2/microglia proposal) is addressed in adversarial check 4 and would be only weakly supported; this divergence is disclosed and does not affect the verdict, which already reports SC3's failure.
Source: proof.py JSON summary claim_formal and claim_natural
| Fact ID | Domain | Type | Note |
|---|---|---|---|
| B1 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B2 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B3 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B4 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B5 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B6 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B7 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
| B8 | nih.gov | Government | Peer-reviewed journal article hosted on NIH/PubMed Central; credibility tier 5 |
All sources are peer-reviewed academic publications accessed via PubMed Central, which the credibility module classifies by its nih.gov government domain (tier 5). No source is flagged unreliable or satire. The verdict does not depend on any low-credibility source.
Source: proof.py JSON summary evidence[*].verification.credibility
SC1 (CB2/microglia mechanism proposed): 3 >= 3 = True
SC2 (central sensitization & microglial activation in fibromyalgia): 3 >= 3 = True
SC3 (all three cited references resolve): 2 >= 3 = False
compound (all sub-claims hold): 2 == 3 = False
n_holding = 2 of n_total = 3 sub-claims. Because some but not all sub-claims hold, the verdict is PARTIALLY VERIFIED.
Source: proof.py inline output (execution trace)
SC1 cross-check. Three sources consulted, three verified. Cabral & Griffin-Thomas (2009), Stella (2010), and Xu et al. (2023) are three separate publications by distinct author groups, spanning 2009 to 2023, with no shared authorship. They independently articulate the CB2-on-microglia mechanism; agreement holds.
SC2 cross-check. Three sources consulted, three verified. A 2025 narrative review (Findeisen et al.), a 2019 multi-site PET primary study (Albrecht et al.), and a 2024 pathophysiology review (Jurado-Priego et al.) — distinct author groups, distinct study types. The set collectively covers both conjuncts of the sub-claim: microglial/glial activation (Findeisen, Albrecht) and central sensitization (Jurado-Priego). Agreement holds.
SC3 cross-check. Three references named in the claim; two resolve and verify (Cabral & Griffin-Thomas 2009; Stella 2010), one does not ("Chen et al., 2023"). Agreement does not hold (2 of 3).
Conflict of interest. The claim concerns the scientific literature itself, not a commercial product or organization, so the standard COI taxonomy (organizational, funding dependency, institutional co-benefit, competitive antagonism, revolving door, advocacy) has no party to attach to. coi_flags is an explicit empty list for each sub-claim. No source has a conflict of interest with the claim's subject; no majority-COI condition applies.
Source: proof.py JSON summary cross_checks
- Rule 1 (no hand-typed values): N/A — qualitative proof, no numeric extraction from quotes.
- Rule 2 (citations fetched and verified): Pass — all eight citations verified via
verify_all_citationsagainst committed snapshots. - Rule 3 (system time): N/A —
CLAIM_FORMAL.is_time_sensitiveis False; the claim is not date-dependent and nodate()logic is used. - Rule 4 (explicit claim interpretation): Pass —
CLAIM_FORMALcarries a compoundoperator_noteand a per-sub-claimoperator_note, including the formalization-scope disclosure for SC1. - Rule 5 (adversarial checks): Pass — four independent counter-evidence investigations recorded.
- Rule 6 (independent cross-checks): Pass — three per-sub-claim cross-checks over distinct author groups; explicit empty
coi_flags. - Rule 7 (no hard-coded constants/formulas): Pass — all evaluations via
compare(); verdict viaapply_verdict_qualifier(). - validate_proof.py result: PASS — 22/22 checks passed, 0 issues, 0 warnings.
Source: proof.py and validate_proof.py output
This is a qualitative/consensus proof: no numeric values were extracted from quote text. The extractions records therefore carry citation-verification status per source rather than parsed values.
| Fact ID | Value | Found in quote | Quote snippet (first 80 chars) |
|---|---|---|---|
| B1 | verified | Yes | This expression of CB2 has been localized primarily to microglia, the resident m |
| B2 | verified | Yes | These receptors are expressed by microglia, astrocytes and astrocytomas, and the |
| B3 | verified | Yes | Accumulating evidence has demonstrated that the expression of CB2 receptors is s |
| B4 | verified | Yes | There is a growing focus on processes occurring in the dorsal root ganglia and t |
| B5 | verified | Yes | While mounting evidence suggests a role for neuroinflammation, no study has dire |
| B6 | verified | Yes | three underlying processes in fibromyalgia have been investigated. These include |
| B7 | verified | Yes | Expert Rev Mol Med. 2009 Jan 20;11:e3. doi: 10.1017/S1462399409000957 |
| B8 | verified | Yes | Glia. 2010 Jul;58(9):1017-1030. doi: 10.1002/glia.20983 |
Extraction method: each quote was confirmed as a verbatim substring of the normalized source page (HTML stripped, Unicode normalized, whitespace collapsed, lowercased) by the bundled verify_citations matcher. No regex value extraction was performed because the claim is qualitative.
Source: proof.py JSON summary evidence[*].extraction; extraction-method narrative is author analysis
| ID | Fact | Verified |
|---|---|---|
| B1 | SC1: Cabral & Griffin-Thomas (2009) — CB2 expression localized primarily to microglia | Yes |
| B2 | SC1: Stella (2010) — CB1/CB2 expressed by microglia; their activation regulates microglial function | Yes |
| B3 | SC1: Xu et al. (2023) — CB2 expression increased in activated microglia in spinal pain circuitry | Yes |
| B4 | SC2: Findeisen et al. (2025) — maladaptive microglial cell activation implicated in fibromyalgia | Yes |
| B5 | SC2: Albrecht et al. (2019) — PET evidence of brain glial activation in fibromyalgia | Yes |
| B6 | SC2: Jurado-Priego et al. (2024) — central sensitization an investigated process in fibromyalgia | Yes |
| B7 | SC3: cited reference 1 (Cabral & Griffin-Thomas, 2009) resolves to a real publication | Yes |
| B8 | SC3: cited reference 2 (Stella, 2010) resolves to a real publication | Yes |
| A1 | SC1 verified-source count | Computed: 3 of 3 sources verified |
| A2 | SC2 verified-source count | Computed: 3 of 3 sources verified |
| A3 | SC3 resolved-citation count | Computed: 2 of 3 cited references resolve; "Chen et al., 2023" not identified |
All eight empirical sources verified as exact-quote matches against committed snapshots of the source pages. Every source is a peer-reviewed publication hosted on PubMed Central (credibility tier 5, government).
Source: proof.py JSON summary
Cite this proof
Proof Engine. (2026). Claim Verification: “Activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, including chronic widespread pain syndromes such as fibromyalgia where central sensitization and microglial activation have been implicated (Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023).” — Partially verified. https://doi.org/10.5281/zenodo.20318616
Proof Engine. "Claim Verification: “Activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, including chronic widespread pain syndromes such as fibromyalgia where central sensitization and microglial activation have been implicated (Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023).” — Partially verified." 2026. https://doi.org/10.5281/zenodo.20318616.
@misc{proofengine_activation_of_cannabinoid_receptor_type_2_cb2_on_microglia_has_been_proposed_as,
title = {Claim Verification: “Activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, including chronic widespread pain syndromes such as fibromyalgia where central sensitization and microglial activation have been implicated (Cabral \& Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023).” — Partially verified},
author = {{Proof Engine}},
year = {2026},
url = {https://proofengine.info/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/},
note = {Verdict: PARTIALLY VERIFIED. Generated by proof-engine v1.34.1},
doi = {10.5281/zenodo.20318616},
}TY - DATA TI - Claim Verification: “Activation of cannabinoid receptor type 2 (CB2) on microglia has been proposed as a mechanism for modulating neuroinflammatory pain states, including chronic widespread pain syndromes such as fibromyalgia where central sensitization and microglial activation have been implicated (Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023).” — Partially verified AU - Proof Engine PY - 2026 UR - https://proofengine.info/proofs/activation-of-cannabinoid-receptor-type-2-cb2-on-microglia-has-been-proposed-as/ N1 - Verdict: PARTIALLY VERIFIED. Generated by proof-engine v1.34.1 DO - 10.5281/zenodo.20318616 ER -
View proof source
This is the exact proof.py that was deposited to Zenodo and runs when you re-execute via Binder. Every fact in the verdict above traces to code below.
"""
Proof: "Activation of cannabinoid receptor type 2 (CB2) on microglia has been
proposed as a mechanism for modulating neuroinflammatory pain states, including
chronic widespread pain syndromes such as fibromyalgia where central
sensitization and microglial activation have been implicated
(Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023)."
Compound empirical claim about the scientific literature. Decomposed into three
sub-claims joined by AND:
SC1 - the CB2/microglia mechanism for neuroinflammatory pain has been proposed;
SC2 - central sensitization and microglial activation are implicated in
fibromyalgia;
SC3 - the three references the claim names all resolve to real, identifiable
publications.
Generated: 2026-05-20
"""
import os
import sys
PROOF_ENGINE_ROOT = os.environ.get("PROOF_ENGINE_ROOT")
if not PROOF_ENGINE_ROOT:
_d = os.path.dirname(os.path.abspath(__file__))
while _d != os.path.dirname(_d):
if os.path.isdir(os.path.join(_d, "proof-engine", "skills", "proof-engine", "scripts")):
PROOF_ENGINE_ROOT = os.path.join(_d, "proof-engine", "skills", "proof-engine")
break
_d = os.path.dirname(_d)
if not PROOF_ENGINE_ROOT:
raise RuntimeError("PROOF_ENGINE_ROOT not set and skill dir not found via walk-up from proof.py")
sys.path.insert(0, PROOF_ENGINE_ROOT)
# PubMed Central (pmc.ncbi.nlm.nih.gov) blocks / truncates automated HTTP
# fetches non-deterministically: an identical request returns the full article
# on one run and a ~21 KB stub on the next. To make this proof fully
# deterministic and offline-reproducible, live fetching is disabled so that
# verification runs against the committed snapshots/ copies (captured
# 2026-05-20 with a browser user-agent). Monkeypatching `requests` on the
# verify module is a documented, supported pattern (see SKILL.md).
import scripts.verify_citations as _vc
_vc.requests = None
from scripts.verify_citations import verify_all_citations # noqa: E402
from scripts.computations import compare, apply_verdict_qualifier # noqa: E402
from scripts.proof_summary import ProofSummaryBuilder # noqa: E402
_PROOF_DIR = os.path.dirname(os.path.abspath(__file__))
def _snap(name):
"""Absolute path to a committed source snapshot."""
return os.path.join(_PROOF_DIR, "snapshots", name)
# ---------------------------------------------------------------------------
# 1. CLAIM INTERPRETATION (Rule 4)
# ---------------------------------------------------------------------------
CLAIM_NATURAL = (
"Activation of cannabinoid receptor type 2 (CB2) on microglia has been "
"proposed as a mechanism for modulating neuroinflammatory pain states, "
"including chronic widespread pain syndromes such as fibromyalgia where "
"central sensitization and microglial activation have been implicated "
"(Cabral & Griffin-Thomas, 2009; Stella, 2010; Chen et al., 2023)."
)
CLAIM_FORMAL = {
"subject": (
"the peer-reviewed literature on CB2-receptor activation on microglia, "
"neuroinflammatory pain, and fibromyalgia, plus the three references "
"the claim cites"
),
"claim_type": "compound_empirical",
"proof_direction": "affirm",
"is_time_sensitive": False,
"sub_claims": [
{
"id": "SC1",
"property": (
"independently published peer-reviewed sources that propose or "
"articulate CB2-receptor activation on microglia as a mechanism "
"for modulating neuroinflammatory pain"
),
"operator": ">=",
"threshold": 3,
"operator_note": (
"Counts independently published peer-reviewed sources that "
"articulate the CB2-on-microglia / neuroinflammatory-pain "
"mechanism. Threshold 3 is the standard consensus floor. The "
"claim's phrase 'including ... fibromyalgia' is read as naming "
"fibromyalgia as an INSTANCE of a neuroinflammatory pain state "
"(a reading justified by SC2); SC1 therefore does NOT require a "
"study that specifically proposed CB2-on-microglia agonism as a "
"fibromyalgia therapy. The claim's verb 'has been proposed' is "
"hedged, hypothesis-level language: the proof verifies that the "
"mechanism has been proposed, NOT that it is a clinically "
"proven fibromyalgia treatment."
),
},
{
"id": "SC2",
"property": (
"independently published peer-reviewed sources implicating "
"central sensitization and microglial activation in fibromyalgia"
),
"operator": ">=",
"threshold": 3,
"operator_note": (
"Counts independently published peer-reviewed sources "
"implicating central sensitization and/or microglial activation "
"in fibromyalgia. Threshold 3 is the standard consensus floor. "
"The two phenomena are evaluated together because the claim "
"conjoins them; the supporting set collectively covers both - "
"microglial / glial activation (Findeisen et al. review; "
"Albrecht et al. PET study) and central sensitization "
"(Jurado-Priego et al. review, which names fibromyalgia "
"explicitly). The verb 'have been implicated' is hedged."
),
},
{
"id": "SC3",
"property": (
"references named in the claim that resolve to a real, "
"identifiable publication on the attributed topic"
),
"operator": ">=",
"threshold": 3,
"operator_note": (
"Citation-integrity check - NOT a consensus count. The claim "
"explicitly cites three references; threshold 3 means all three "
"must resolve to a real, identifiable publication. Empirical "
"facts sc3_cabral and sc3_stella confirm two of them "
"(Cabral & Griffin-Thomas, 2009; Stella, 2010). There is NO "
"empirical fact for the third reference, 'Chen et al., 2023', "
"because systematic PubMed searches (adversarial check AC3) "
"found no publication matching that citation on this topic. "
"The absence of a third empirical fact is itself the evidence "
"that SC3 fails: n_sc3 = 2 < 3."
),
},
],
"compound_operator": "AND",
"operator_note": (
"The claim is taken as a complete unit - the sentence AND its "
"parenthetical citation list - and decomposed into three sub-claims "
"joined by AND. SC1 and SC2 test the two scientific propositions; SC3 "
"tests the integrity of the three references the claim names. All "
"three sub-claims must hold for the claim to be fully PROVED. The "
"claim's verbs ('has been proposed', 'have been implicated') are "
"deliberately hedged, hypothesis-level language; this proof verifies "
"exactly that hedged form and does not test clinical efficacy."
),
}
# Reference inventory the claim asserts. SC3 tests whether each resolves.
# This is documentation only; the SC3 verdict is computed from citation
# verification results below, not from this table.
CITED_REFERENCES = [
"Cabral & Griffin-Thomas, 2009 -> resolves (Expert Rev Mol Med 11:e3; PMC2768535)",
"Stella, 2010 -> resolves (Glia 58(9):1017-1030; PMC2919281)",
"Chen et al., 2023 -> NOT identified (see adversarial check AC3)",
]
# ---------------------------------------------------------------------------
# 2. FACT REGISTRY
# ---------------------------------------------------------------------------
FACT_REGISTRY = {
"B1": {"key": "sc1_cabral", "label": "SC1: Cabral & Griffin-Thomas (2009) - CB2 localized to microglia"},
"B2": {"key": "sc1_stella", "label": "SC1: Stella (2010) - CB2 on microglia; activation regulates microglial function"},
"B3": {"key": "sc1_xu", "label": "SC1: Xu et al. (2023) - CB2 on activated microglia in spinal pain circuitry"},
"B4": {"key": "sc2_brainsci", "label": "SC2: Findeisen et al. (2025) - maladaptive microglial activation in fibromyalgia"},
"B5": {"key": "sc2_albrecht", "label": "SC2: Albrecht et al. (2019) - PET evidence of brain glial activation in fibromyalgia"},
"B6": {"key": "sc2_jurado", "label": "SC2: Jurado-Priego et al. (2024) - central sensitization as a process in fibromyalgia"},
"B7": {"key": "sc3_cabral", "label": "SC3: cited reference 1 - Cabral & Griffin-Thomas (2009) resolves to a real publication"},
"B8": {"key": "sc3_stella", "label": "SC3: cited reference 2 - Stella (2010) resolves to a real publication"},
"A1": {"label": "SC1 verified-source count", "method": None, "result": None},
"A2": {"label": "SC2 verified-source count", "method": None, "result": None},
"A3": {"label": "SC3 resolved-citation count", "method": None, "result": None},
}
# ---------------------------------------------------------------------------
# 3. EMPIRICAL FACTS - grouped by sub-claim (Rule 2)
# Quotes are verbatim substrings of the committed snapshots/ copies.
# ---------------------------------------------------------------------------
empirical_facts = {
# --- SC1: CB2-on-microglia mechanism for neuroinflammatory pain ---
"sc1_cabral": {
"quote": "This expression of CB2 has been localized primarily to microglia, the resident macrophages of the CNS.",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2768535/",
"source_name": "Cabral GA & Griffin-Thomas L (2009), 'Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation', Expert Reviews in Molecular Medicine 11:e3 (PubMed Central PMC2768535)",
"snapshot_file": _snap("cabral2009.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
"sc1_stella": {
"quote": "These receptors are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells’ differentiation, functions and viability.",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2919281/",
"source_name": "Stella N (2010), 'Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas', Glia 58(9):1017-1030 (PubMed Central PMC2919281)",
"snapshot_file": _snap("stella2010.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
"sc1_xu": {
"quote": "Accumulating evidence has demonstrated that the expression of CB2 receptors is significantly increased in activated microglia in the spinal cord",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9917135/",
"source_name": "Xu K, Wu Y, Tian Z, et al. (2023), 'Microglial Cannabinoid CB2 Receptors in Pain Modulation', International Journal of Molecular Sciences 24(3):2348 (PubMed Central PMC9917135)",
"snapshot_file": _snap("xu2023.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
# --- SC2: central sensitization & microglial activation in fibromyalgia ---
"sc2_brainsci": {
"quote": "There is a growing focus on processes occurring in the dorsal root ganglia and the role of maladaptive microglial cell activation.",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11852494/",
"source_name": "Findeisen K, Guymer E, Littlejohn G (2025), 'Neuroinflammatory and Immunological Aspects of Fibromyalgia', Brain Sciences 15(2):206 (PubMed Central PMC11852494)",
"snapshot_file": _snap("fm_brainsci2025.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
"sc2_albrecht": {
"quote": "While mounting evidence suggests a role for neuroinflammation, no study has directly provided evidence of brain glial activation in FM.",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6541932/",
"source_name": "Albrecht DS, Forsberg A, Sandstrom A, et al. (2019), 'Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation', Brain, Behavior, and Immunity 75:72-83 (PubMed Central PMC6541932)",
"snapshot_file": _snap("albrecht2019.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
"sc2_jurado": {
"quote": "three underlying processes in fibromyalgia have been investigated. These include central sensitization, associated with an increase in the release of both excitatory and inhibitory neurotransmitters",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11275111/",
"source_name": "Jurado-Priego LN, Cueto-Urena C, Ramirez-Exposito MJ, Martinez-Martos JM (2024), 'Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Approaches', Biomedicines 12(7):1543 (PubMed Central PMC11275111)",
"snapshot_file": _snap("jurado2024.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
# --- SC3: do the cited references resolve to real publications? ---
"sc3_cabral": {
"quote": "Expert Rev Mol Med. 2009 Jan 20;11:e3. doi: 10.1017/S1462399409000957",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2768535/",
"source_name": "PubMed Central bibliographic record for Cabral & Griffin-Thomas (2009), PMC2768535",
"snapshot_file": _snap("cabral2009.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
"sc3_stella": {
"quote": "Glia. 2010 Jul;58(9):1017-1030. doi: 10.1002/glia.20983",
"url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2919281/",
"source_name": "PubMed Central bibliographic record for Stella (2010), PMC2919281",
"snapshot_file": _snap("stella2010.html"),
"snapshot_source": "public:pre_fetched",
"snapshot_fetched_at": "2026-05-20",
},
}
# ---------------------------------------------------------------------------
# 4. CITATION VERIFICATION (Rule 2)
# ---------------------------------------------------------------------------
citation_results = verify_all_citations(empirical_facts, wayback_fallback=False)
# ---------------------------------------------------------------------------
# 5. COUNT VERIFIED SOURCES PER SUB-CLAIM
# ---------------------------------------------------------------------------
COUNTABLE_STATUSES = ("verified", "partial")
sc1_keys = [k for k in empirical_facts if k.startswith("sc1_")]
sc2_keys = [k for k in empirical_facts if k.startswith("sc2_")]
sc3_keys = [k for k in empirical_facts if k.startswith("sc3_")]
n_sc1 = sum(1 for k in sc1_keys if citation_results[k]["status"] in COUNTABLE_STATUSES)
n_sc2 = sum(1 for k in sc2_keys if citation_results[k]["status"] in COUNTABLE_STATUSES)
n_sc3 = sum(1 for k in sc3_keys if citation_results[k]["status"] in COUNTABLE_STATUSES)
# ---------------------------------------------------------------------------
# 6. PER-SUB-CLAIM EVALUATION (Rule 7 - compare(), no hardcoded booleans)
# ---------------------------------------------------------------------------
sc1_holds = compare(n_sc1, ">=", CLAIM_FORMAL["sub_claims"][0]["threshold"],
label="SC1 (CB2/microglia mechanism proposed)")
sc2_holds = compare(n_sc2, ">=", CLAIM_FORMAL["sub_claims"][1]["threshold"],
label="SC2 (central sensitization & microglial activation in fibromyalgia)")
sc3_holds = compare(n_sc3, ">=", CLAIM_FORMAL["sub_claims"][2]["threshold"],
label="SC3 (all three cited references resolve)")
# ---------------------------------------------------------------------------
# 7. COMPOUND EVALUATION
# ---------------------------------------------------------------------------
sub_claim_outcomes = [sc1_holds, sc2_holds, sc3_holds]
n_holding = sum(sub_claim_outcomes)
n_total = len(CLAIM_FORMAL["sub_claims"])
claim_holds = compare(n_holding, "==", n_total, label="compound (all sub-claims hold)")
# ---------------------------------------------------------------------------
# 8. CONFLICT-OF-INTEREST FLAGS (Rule 6) - per sub-claim
# The claim concerns the scientific literature, not a commercial entity;
# every source is an independent academic publication. No COI identified.
# ---------------------------------------------------------------------------
sc1_coi_flags = []
sc2_coi_flags = []
sc3_coi_flags = []
# ---------------------------------------------------------------------------
# 9. ADVERSARIAL CHECKS (Rule 5) - documentation of Step-2 counter-research
# ---------------------------------------------------------------------------
adversarial_checks = [
{
"question": (
"Is the CB2-on-microglia mechanism for neuroinflammatory pain a "
"genuine, proposed research mechanism - or is it fringe / disputed?"
),
"verification_performed": (
"Searched PubMed and the web for reviews and primary literature on "
"CB2 receptors, microglia and pain ('CB2 microglia pain "
"modulation', 'cannabinoid CB2 neuroinflammation', 'cannabinoid "
"fibromyalgia efficacy'). Cross-checked whether cannabinoids are "
"an established fibromyalgia treatment."
),
"finding": (
"The CB2-on-microglia mechanism for modulating neuroinflammatory "
"pain is a well-established research hypothesis, articulated "
"across many independent peer-reviewed reviews from 2009 to 2023 - "
"not a fringe claim. Counter-point: clinical efficacy of "
"cannabinoids in fibromyalgia SPECIFICALLY remains inconsistent "
"and unproven. This does not break SC1, because the claim asserts "
"only that the mechanism 'has been proposed' (hypothesis-level "
"language), not that it is a clinically proven treatment; the "
"hedged wording is accurate. The unproven-efficacy point is "
"recorded so the claim is not over-read."
),
"breaks_proof": False,
},
{
"question": (
"Is microglial activation in fibromyalgia disputed - e.g. is the "
"Albrecht et al. (2019) glial-activation PET finding contradicted?"
),
"verification_performed": (
"Searched for replication and criticism of glial-activation "
"findings in fibromyalgia ('fibromyalgia microglia PET "
"criticism', 'fibromyalgia neuroinflammation replication', "
"'TSPO PET limitations')."
),
"finding": (
"TSPO-PET evidence of glial activation in fibromyalgia has "
"acknowledged limitations (the TSPO tracer is not microglia-"
"specific; sample sizes are modest), and it remains an area of "
"active research. But the broader implication - that "
"neuroinflammation / microglial activation and central "
"sensitization are involved in fibromyalgia - is supported by "
"converging evidence (PET imaging, CSF cytokines, multiple "
"narrative reviews). No authoritative source rejects the "
"implication. The claim's verb 'have been implicated' is "
"appropriately hedged, so the TSPO caveats do not break SC2."
),
"breaks_proof": False,
},
{
"question": (
"Does the cited reference 'Chen et al., 2023' correspond to a "
"real, identifiable publication supporting the attributed content?"
),
"verification_performed": (
"Systematic PubMed searches via NCBI E-utilities and the PubMed "
"web interface: (1) Chen[au] AND 2023[dp] AND (CB2 OR cannabinoid) "
"AND microglia AND pain -> 1 hit, Chen L et al., 'Assessing "
"Cannabidiol as a Therapeutic Agent for Preventing and "
"Alleviating Alzheimer's Disease Neurodegeneration', Cells 2023 "
"(off-topic: cannabidiol / Alzheimer's, not CB2 / microglia / "
"pain). (2) Chen[au] AND 2023[dp] AND cannabinoid AND microglia "
"-> 7 hits, no Chen-first-author paper on CB2 / microglia / pain. "
"(3) Chen[au] AND 2023[dp] AND fibromyalgia -> 25 hits, none a "
"Chen-first-author cannabinoid / CB2 / microglia paper. "
"(4) Chen[au] AND 2023[dp] AND CB2 AND pain -> 1 hit, first "
"author Nan, not Chen. Web searches likewise surfaced the only "
"on-topic 2023 review, 'Microglial Cannabinoid CB2 Receptors in "
"Pain Modulation' (first author Xu, not Chen), and 'Spinal "
"cannabinoid receptor 2 activation alleviates neuropathic pain "
"by regulating microglia' (first author Zhou, not Chen). "
"PubMed query URLs: "
"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5Bau%5D+AND+2023%5Bdp%5D+AND+cannabinoid+AND+microglia ; "
"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5Bau%5D+AND+2023%5Bdp%5D+AND+fibromyalgia"
),
"finding": (
"No publication matching 'Chen et al., 2023' on CB2 / microglia / "
"neuroinflammatory pain or fibromyalgia could be identified. The "
"two genuinely on-topic 2023 papers have first authors Xu and "
"Zhou, not Chen. This is the evidence underlying SC3's failure: "
"one of the three references named in the claim is unverifiable, "
"a pattern consistent with a misattributed or fabricated "
"(hallucinated) citation. It does NOT break the proof and is not "
"forced to UNDETERMINED, because SC1 and SC2 are independently "
"established and SC3's failure is already captured by the "
"compound verdict. breaks_proof is therefore False."
),
"breaks_proof": False,
},
{
"question": (
"Does the claim require a source that specifically proposed "
"CB2-on-microglia modulation as a fibromyalgia treatment?"
),
"verification_performed": (
"Re-read the claim's grammar and searched for CB2 / microglia "
"proposals targeting fibromyalgia specifically ('CB2 receptor "
"microglia fibromyalgia', 'endocannabinoid system fibromyalgia')."
),
"finding": (
"Under the natural reading, 'including chronic widespread pain "
"syndromes such as fibromyalgia' names fibromyalgia as an "
"INSTANCE of the neuroinflammatory pain states for which the "
"mechanism is proposed - a reading bridged by SC2, which "
"establishes that fibromyalgia is characterized by central "
"sensitization and microglial activation. The claim does not "
"assert that a specific study tested CB2-on-microglia agonism in "
"fibromyalgia patients, and this proof does not rely on one. A "
"stricter reading (a dedicated fibromyalgia-specific CB2/microglia "
"proposal) would be only weakly supported; that scope limitation "
"is disclosed here and in proof.md. It does not change the "
"verdict, which already reports SC3's failure."
),
"breaks_proof": False,
},
]
# ---------------------------------------------------------------------------
# 10. VERDICT
# ---------------------------------------------------------------------------
if __name__ == "__main__":
any_unverified = any(cr["status"] != "verified" for cr in citation_results.values())
any_breaks = any(ac.get("breaks_proof") for ac in adversarial_checks)
is_disproof = CLAIM_FORMAL.get("proof_direction") == "disprove"
if any_breaks:
base_verdict = "UNDETERMINED"
elif claim_holds:
base_verdict = "DISPROVED" if is_disproof else "PROVED"
elif n_holding > 0:
base_verdict = "PARTIALLY VERIFIED"
else:
base_verdict = "UNDETERMINED"
verdict = apply_verdict_qualifier(base_verdict, any_unverified)
# ----- Human-readable trace -----
print("=" * 72)
print("PROOF: CB2-on-microglia / neuroinflammatory pain / fibromyalgia claim")
print("=" * 72)
print("\nCLAIM:\n " + CLAIM_NATURAL)
print("\nCITED-REFERENCE INVENTORY (SC3):")
for r in CITED_REFERENCES:
print(" - " + r)
print("\nCITATION VERIFICATION:")
for k, cr in citation_results.items():
print(f" {k:14s} {cr['status']:10s} (mode={cr.get('fetch_mode')})")
print("\nSUB-CLAIM RESULTS:")
print(f" SC1 verified sources = {n_sc1}/3 -> holds={sc1_holds}")
print(f" SC2 verified sources = {n_sc2}/3 -> holds={sc2_holds}")
print(f" SC3 resolved citations = {n_sc3}/3 -> holds={sc3_holds}")
print(f"\n Sub-claims holding: {n_holding}/{n_total}")
print(f" Compound (all hold): {claim_holds}")
print(f" Any citation unverified: {any_unverified}")
print(f"\nVERDICT: {verdict}")
print("=" * 72)
# ----- Structured proof summary -----
builder = ProofSummaryBuilder(CLAIM_NATURAL, CLAIM_FORMAL)
def _sub_of(ef_key):
if ef_key in sc1_keys:
return "SC1"
if ef_key in sc2_keys:
return "SC2"
return "SC3"
for fid, info in FACT_REGISTRY.items():
if not fid.startswith("B"):
continue
ef_key = info["key"]
ef = empirical_facts[ef_key]
cr = citation_results.get(ef_key, {})
builder.add_empirical_fact(
fid,
label=info["label"],
source_name=ef["source_name"],
source_url=ef["url"],
source_quote=ef["quote"],
sub_claim=_sub_of(ef_key),
)
builder.set_verification(
fid,
status=cr.get("status", "unknown"),
method=cr.get("method", "full_quote") or "full_quote",
coverage_pct=cr.get("coverage_pct"),
fetch_mode=cr.get("fetch_mode", "snapshot"),
credibility=cr.get("credibility", {}),
)
builder.set_extraction(
fid,
value=cr.get("status", "unknown"),
value_in_quote=cr.get("status") in COUNTABLE_STATUSES,
quote_snippet=ef["quote"][:80],
)
sc1_fact_ids = [fid for fid, info in FACT_REGISTRY.items()
if fid.startswith("B") and info["key"] in sc1_keys]
sc2_fact_ids = [fid for fid, info in FACT_REGISTRY.items()
if fid.startswith("B") and info["key"] in sc2_keys]
sc3_fact_ids = [fid for fid, info in FACT_REGISTRY.items()
if fid.startswith("B") and info["key"] in sc3_keys]
builder.add_computed_fact(
"A1", label="SC1 verified-source count",
method=f"count(verified SC1 citations) = {n_sc1}",
result=n_sc1, depends_on=sc1_fact_ids, sub_claim="SC1",
)
builder.add_computed_fact(
"A2", label="SC2 verified-source count",
method=f"count(verified SC2 citations) = {n_sc2}",
result=n_sc2, depends_on=sc2_fact_ids, sub_claim="SC2",
)
builder.add_computed_fact(
"A3", label="SC3 resolved-citation count",
method=(f"count(cited references resolving to a real publication) "
f"= {n_sc3}; the claim names 3 references, so n_sc3 < 3 "
f"means at least one citation is unverifiable"),
result=n_sc3, depends_on=sc3_fact_ids, sub_claim="SC3",
)
builder.add_cross_check(
description="SC1: independent peer-reviewed sources for the CB2/microglia mechanism",
fact_ids=sc1_fact_ids,
n_sources_consulted=len(sc1_keys),
n_sources_verified=n_sc1,
sources={k: citation_results[k]["status"] for k in sc1_keys},
independence_note=("Three separate publications, distinct author groups, "
"spanning 2009-2023; no shared authorship and no COI "
"with a commercial subject."),
coi_flags=sc1_coi_flags,
agreement=sc1_holds,
)
builder.add_cross_check(
description="SC2: independent peer-reviewed sources for fibromyalgia neuro-immune features",
fact_ids=sc2_fact_ids,
n_sources_consulted=len(sc2_keys),
n_sources_verified=n_sc2,
sources={k: citation_results[k]["status"] for k in sc2_keys},
independence_note=("A 2025 narrative review, a 2019 multi-site PET primary "
"study, and a 2024 pathophysiology review - distinct "
"author groups; collectively cover microglial activation "
"and central sensitization."),
coi_flags=sc2_coi_flags,
agreement=sc2_holds,
)
builder.add_cross_check(
description="SC3: do the three references named in the claim resolve to real publications?",
fact_ids=sc3_fact_ids,
n_sources_consulted=3,
n_sources_verified=n_sc3,
sources={k: citation_results[k]["status"] for k in sc3_keys},
independence_note=("Two of the three named references resolve and verify "
"(Cabral & Griffin-Thomas 2009; Stella 2010). The third, "
"'Chen et al., 2023', was searched systematically in "
"PubMed and could not be identified - see adversarial "
"check AC3. n_sc3 = 2 < 3."),
coi_flags=sc3_coi_flags,
agreement=sc3_holds,
)
builder.add_sub_claim_result(
id="SC1", n_confirming=n_sc1,
threshold=CLAIM_FORMAL["sub_claims"][0]["threshold"], holds=sc1_holds,
)
builder.add_sub_claim_result(
id="SC2", n_confirming=n_sc2,
threshold=CLAIM_FORMAL["sub_claims"][1]["threshold"], holds=sc2_holds,
)
builder.add_sub_claim_result(
id="SC3", n_confirming=n_sc3,
threshold=CLAIM_FORMAL["sub_claims"][2]["threshold"], holds=sc3_holds,
)
for ac in adversarial_checks:
builder.add_adversarial_check(
question=ac["question"],
verification_performed=ac["verification_performed"],
finding=ac["finding"],
breaks_proof=ac["breaks_proof"],
)
builder.set_verdict(base_verdict, any_unverified=any_unverified)
builder.set_key_results(
n_holding=n_holding,
n_total=n_total,
claim_holds=claim_holds,
sc1_holds=sc1_holds,
sc2_holds=sc2_holds,
sc3_holds=sc3_holds,
unidentified_citation="Chen et al., 2023",
)
builder.set_extra("verdict_note", (
"PARTIALLY VERIFIED: the two scientific propositions (SC1, SC2) are "
"verified and well-supported; the citation-integrity sub-claim (SC3) "
"fails because one of the three references the claim names, "
"'Chen et al., 2023', could not be identified as a real publication."
))
builder.emit()
Re-execute this proof
The verdict above is cached from when this proof was minted. To re-run the exact
proof.py shown in "View proof source" and see the verdict recomputed live,
launch it in your browser — no install required.
Re-execute the exact bytes deposited at Zenodo.
Re-execute in Binder runs in your browser · ~60s · no installFirst run takes longer while Binder builds the container image; subsequent runs are cached.
machine-readable formats
Downloads & raw data
Embed this proof
Cite this proof in your wiki, docs, or README:
Preview:
found this useful? ★ star on github